Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors

被引:15
作者
Davin, Laurent [1 ,2 ]
Marechal, Patrick [1 ]
Lancellotti, Patrizio [1 ,2 ]
Martinez, Christophe [1 ]
Pierard, Luc [1 ,2 ]
Radermecker, Regis [3 ,4 ]
机构
[1] Univ Liege Hosp, CHU Sart Tilman, Dept Cardiol, Liege, Belgium
[2] Univ Hosp Liege, GIGA Cardiovasc Sci, Liege, Belgium
[3] CHU Liege, Diabet Nutr & Metab Disorders Unit, Liege, Belgium
[4] Univ Liege, Clin Pharmacol, Liege, Belgium
关键词
Angioedema; angiotensin converting enzyme inhibitor; allergy; LATE-ONSET ANGIOEDEMA; ACE-INHIBITORS; BRADYKININ; RISK; DRUGS; EDEMA;
D O I
10.1080/00015385.2018.1507477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of angiotensin converting enzyme (ACE) inhibitors result from the inhibition of the ACE (kininase II) to ultimately influence both the renin-angiotensin system and the degradation of the bradykinin (BK) metabolism. ACE inhibitors block the degradation of BK and substance P by ACE. In addition, an active metabolite of BK (Des-Arg9-BK) is catalysed by kininase I and its degradation is controlled in part by the conversion enzyme. These molecules have been associated with increased plasma extravasation associated with ACE inhibitors. ACE inhibitors are the leading cause of drug-induced Angioedema (AE). Symptoms of AE mainly occur after the first month of treatment by ACE. However, very late onset cases, sometimes after several years of stable therapy, are also described in the literature. It has been observed that patients previously stable under ACE inhibitor will most likely develop AE soon after the addition of another medication, including the combination of aspirin or non-steroid anti-inflammatory drugs with ACE inhibitor which has proved to be the most common cause, accounting for close to 50% of all AE cases related to ACE inhibitors. This side effect of ACE inhibitors, sometimes very late and rare, deserves to be recalled
引用
收藏
页码:277 / 281
页数:5
相关论文
共 37 条
[1]   Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors [J].
Adam, A ;
Cugno, M ;
Molinaro, G ;
Perez, M ;
Lepage, Y ;
Agostoni, A .
LANCET, 2002, 359 (9323) :2088-2089
[2]   Angioedema: The role of ACE inhibitors and factors associated with poor clinical outcome [J].
Agah, R ;
Bandi, V ;
Guntupalli, KK .
INTENSIVE CARE MEDICINE, 1997, 23 (07) :793-796
[3]   Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department [J].
Banerji, Aleena ;
Clark, Sunday ;
Blanda, Michelle ;
LoVecchio, Frank ;
Snyder, Brian ;
Camargo, Carlos A., Jr. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (04) :327-332
[4]   Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record [J].
Banerji, Aleena ;
Blumenthal, Kimberly G. ;
Lai, Kenneth H. ;
Zhou, Li .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (03) :744-749
[5]   Increased C-reactive protein in ACE-inhibitor-induced angioedema [J].
Bas, M ;
Hoffmann, TK ;
Bier, H ;
Kojda, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (02) :233-238
[6]   Recurrent angiotensin-converting enzyme inhibitor-associated angioedema [J].
Brown, NJ ;
Snowden, M ;
Griffin, MR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (03) :232-233
[7]   Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema [J].
Brown, NJ ;
Ray, WA ;
Snowden, M ;
Griffin, MR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :8-13
[8]   Neurokinin mediation of edema and inflammation [J].
Campos, MM ;
Calixto, JB .
NEUROPEPTIDES, 2000, 34 (05) :314-322
[9]  
CHEN HM, 1993, J BIOL CHEM, V268, P25311
[10]   Angioedema associated with angiotensin-converting enzyme inhibitor use - Outcome after switching to a different treatment [J].
Cicardi, M ;
Zingale, LC ;
Bergamaschini, L ;
Agostoni, A .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (08) :910-913